NM_000277.3(PAH):c.1174T>A (p.Phe392Ile)

For PAH c.1174T>A (p.Phe392Ile), a pathogenic missense variant in the tetramerization domain of phenylalanine hydroxylase, sapropterin dihydrochloride (Kuvan, BioMarin) — a synthetic formulation of the natural PAH cofactor tetrahydrobiopterin (BH4) — represents a genotype-guided oral pharmacological therapy. Sapropterin acts as both a cofactor supplement and pharmacological chaperone, stabilizing the misfolded PAH protein and enhancing residual enzymatic activity. Phe392 is located at the interface between the catalytic and tetramerization domains; the F392I substitution destabilizes the tetrameric quaternary structure required for full enzymatic activity. BH4-responsive variants are typically missense mutations that retain some folding capacity — the mutant protein is produced but unstable, and BH4 binding thermodynamically stabilizes the active conformation.

Sapropterin received FDA approval in 2007 for BH4-responsive PKU based on the PKU-001 and PKU-003 Phase 3 trials, which demonstrated significant blood Phe reduction in responsive patients (PMID: 17576681). BH4 responsiveness is genotype-dependent: approximately 25-50% of PKU patients carry at least one BH4-responsive allele. The BioPKU database catalogs PAH genotype-phenotype correlations and BH4 responsiveness predictions for individual variants. For p.Phe392Ile specifically, structural modeling predicts that BH4 binding at the active site stabilizes the catalytic domain fold and indirectly supports tetramerization. In vitro expression studies and clinical BH4 loading tests are the standard methods for confirming responsiveness. Pegvaliase (Palynziq), a PEGylated recombinant phenylalanine ammonia lyase (enzyme substitution therapy), provides an alternative mechanism for Phe reduction in patients who are BH4-non-responsive, achieving blood Phe normalization regardless of genotype.

Sapropterin response is inherently genotype-dependent and only partially effective: most responsive patients achieve 30-50% Phe reduction, often requiring continued dietary phenylalanine restriction (though less stringent than without treatment). Complete normalization of blood Phe on sapropterin alone is uncommon. For p.Phe392Ile, BH4 responsiveness must be confirmed empirically via a BH4 loading test (typically 20 mg/kg/day for 24-48 hours with serial Phe measurements), as in silico predictions are not fully reliable. The tetramerization domain location of this variant may limit BH4 chaperone efficacy since BH4 binds the active site rather than the tetramerization interface — stabilization is indirect. Sapropterin costs approximately $100,000-200,000/year and requires lifelong daily oral administration. Patients homozygous for null variants (frameshifts, nonsense, large deletions) are universally BH4-non-responsive because there is no protein to stabilize. For these patients, pegvaliase or gene therapy approaches are more appropriate.